Military Personnel Drug Abuse Testing Program (MPDATP)
|Publication Date:||13 September 2012|
PURPOSE. This Instruction:
a. Reissues DoD Directive (DoDD) 1010.1 (Reference (a)) as a DoD Instruction (DoDI) in accordance with the authority in DoDD 5124.02 (Reference (b)).
b. Updates established policy and assigned responsibilities of the MPDATP. MPDATP guidance is provided in Enclosure 2.
c. Realigns responsibilities for drug detection and deterrence policy, education, and oversight in accordance with the policy in DoDD 1010.4 (Reference (c)). Technical guidance for the Forensic Drug Testing Laboratories is provided in DoDI 1010.16 (Reference (d)).
d. Incorporates and cancels the Assistant Secretary of Defense for Special Operations and Low Intensity Conflict memorandum (Reference (e)).
e. Issues guidance on the conduct of prevalence testing and the use of data from urinalysis testing to conduct demographic longitudinal, statistical, and analytical studies assessing the extent of drug abuse among military personnel within DoD.
APPLICABILITY. This Instruction:
a. Applies to OSD, the Military Departments, the Office of the Chairman of the Joint Chiefs of Staff and the Joint Staff, the Combatant Commands, the Office of the Inspector General of the Department of Defense, the Defense Agencies, the DoD Field Activities, and all other organizational entities within the DoD. The term "Military Services" as used herein, refers to the Army, Navy, Air Force, Marine Corps, Active and Reserve Components.
b. Does not encompass testing in direct support of criminal investigations or clinical diagnostic procedures.